Clinical Report: Evaluating the Prognostic Value of the Modified Advanced Lung Cancer Inflammation Index

Overview

This study investigates the prognostic significance of the modified Advanced Lung Cancer Inflammation Index (mALI) in patients with locally advanced resectable gastric cancer undergoing neoadjuvant chemotherapy. High mALI values were associated with improved overall survival.

Background

Gastric cancer is a leading cause of cancer-related mortality worldwide, and neoadjuvant chemotherapy is increasingly utilized to improve surgical outcomes. Sarcopenia and systemic inflammation are critical factors influencing prognosis in cancer patients.

Data Highlights

Key Findings

• High mALI was associated with improved overall survival (OS) in patients undergoing neoadjuvant chemotherapy.
• Bayesian sensitivity analyses confirmed the association between high mALI and OS.
• Quartile-based analysis indicated a protective trend with higher mALI values (P for trend = 0.033).
• The mALI-based nomogram demonstrated an apparent C-index of 0.765.
• Incorporating mALI into a base model improved model fit significantly (P=0.012).

Clinical Implications

Further validation of mALI is necessary before its routine clinical application.

Conclusion

Preoperative mALI is associated with overall survival in gastric cancer patients undergoing neoadjuvant chemotherapy.

Related Resources & Content

1. Gastric Cancer — The Role of Inflammatory and Nutritional Biomarkers in Predicting Survival Outcomes for Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy and D2 Lymphadenectomy
2. Clinical Implications of Serum Inflammatory Biomarkers in Gastric Cancer Prognosis
3. Preoperative Neutrophil-to-Lymphocyte Ratio as an Independent Prognostic Indicator in Gastric Cancer Patients with Postoperative Complications Following Curative Resection
4. Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment
5. Frontiers in Immunology — An integrated SII-PNI immune-nutritional scoring system predicts efficacy and immune-related adverse events in locally advanced gastric cancer patients undergoing neoadjuvant immunotherapy
6. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
7. Japanese gastric cancer treatment guidelines 2025 (7th edition)
8. J Gastric Cancer. 2025 Jan;25(1):153-176
9. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial - PubMed
10. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer - PubMed
11. Perioperative Treatment With Durvalumab and FLOT Chemotherapy Can Reduce Risk of Recurrence for Some Patients With Gastric Cancers - ASCO
12. Oncology (Cancer)/Hematologic Malignancies Approval Notifications | FDA
13. KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer - PMC
14. Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of locally advanced gastric cancer | BMC Cancer | Springer Nature Link
15. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002 - PubMed
16. Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis - PubMed
17. Frontiers | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy
18. Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment - PMC